Title,Time,Link,Image URL,Teaser,Source Name
Dementia Risk Doubled in Acute Kidney Injury,2024-09-03 07:01:00,https://www.news-medical.net/news/20240829/Acute-kidney-injury-doubles-dementia-risk-study-finds.aspx,https://medsii.azureedge.net/images/638609436591592967-66d6b37f6157181811bbca62.jpg,"A study found a strong link between acute kidney injury (AKI) and a higher likelihood of developing dementia, especially in cases of severe or repeated AKI episodes.",News Medical Life Sciences
Altered Voice Pitch in Diabetes May Offer Diagnosis,2024-09-03 06:53:00,https://www.news-medical.net/news/20240828/Study-confirms-the-link-between-blood-glucose-levels-and-voice-pitch-in-people-with-Type-2-diabetes.aspx,https://medsii.azureedge.net/images/638609429472296586-66d6b0b04e2a8b3bb8355b30.jpg,"Klick Labs published a study in Scientific Reports confirming a link between blood glucose levels and voice pitch, suggesting potential for non-invasive glucose monitoring for individuals with Type 2 diabetes.",News Medical Life Sciences
Moderna's RSV Vaccine Approved in the EU for Over 60s,2024-09-03 06:52:00,https://medicalxpress.com/news/2024-08-eu-moderna-rsv-vaccine-60s.html,https://medsii.azureedge.net/images/638609431326319593-66d6b1a06157181811bbca61.jpg,"The European Commission has approved Moderna's mRNA vaccine for respiratory syncytial virus (RSV) in older adults, marking the first mRNA shot authorized in the EU for a disease other than COVID-19. RSV is a contagious virus that affects both infants and the elderly, leading to hospitalizations in thousands of individuals annually. This approval follows a positive assessment by the European Medicines Agency in June 2024 and highlights the importance of innovation in protecting public health. ",MedicalXpress
EU Approves First Pan-FGFR Bladder Cancer Drug Balversa,2024-09-03 06:42:00,https://pharmaphorum.com/news/jjs-balversa-first-pan-fgfr-bladder-cancer-drug-eu,https://medsii.azureedge.net/images/638609425471085305-66d6aec84e2a8b3bb8355b2f.jpg,"Johnson & Johnson's Balversa has received approval in the EU to treat advanced urothelial carcinoma with FGFR3 genetic alterations after one prior therapy. This approval follows a similar clearance in the US. Balversa can be used as a monotherapy for patients who have previously been treated with a PD-1/PD-L1 inhibitor. The drug showed promising results in a phase 3 study, reducing the risk of death compared to chemotherapy. Balversa is also being tested in high-risk non-muscle-invasive bladder cancer. ",Pharmaphorum
FDA Rare Drug Designation to NXP800 in Ovarian Cancers,2024-09-03 06:34:00,https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-nxp800-for-arid1a-deficient-ovarian-cancers,https://medsii.azureedge.net/images/638609420795429892-66d6ad144e2a8b3bb8355b2e.jpg,"NXP800 was granted orphan drug designation by the FDA for the treatment of ARID1a-deficient ovarian, fallopian tube, and primary peritoneal cancers.",OncLive
